|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...3637383940414243444546...156157» |
- leuprolide acetate for depot suspension / Generic mfg., cyclophosphamide / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: LUPRON: GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases (clinicaltrials.gov) - May 13, 2016
P3, N=14, Terminated, Sponsor: Joseph Mccune
N=75 --> 14 | Recruiting --> Terminated | Trial primary completion date: May 2016 --> Oct 2015
- || smart insulin (MK-2640) / Merck (MSD)
Enrollment closed: A Three-part Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-2640 in Healthy Participants (Part I) and Participants With Type 1 Diabetes Mellitus (Parts II and III) (MK-2640-001) (clinicaltrials.gov) - May 13, 2016
P1, N=74, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
N=75 --> 14 | Recruiting --> Terminated | Trial primary completion date: May 2016 --> Oct 2015 Recruiting --> Active, not recruiting
- Trial completion: Access, Use and Opinions of Physiotherapy and Rehabilitation Services of People With Progressive MS in the UK. (clinicaltrials.gov) - May 13, 2016
P=N/A, N=1298, Completed, Sponsor: University of Glasgow
Recruiting --> Active, not recruiting Recruiting --> Completed
- || Trial primary completion date: PRISM: Pictorial Representation of Illness and Self Measure (clinicaltrials.gov) - May 13, 2016
P=N/A, N=220, Active, not recruiting, Sponsor: University of Oxford
Recruiting --> Completed Trial primary completion date: Jan 2016 --> Dec 2016
- New trial, HEOR: ms-intakt: Effect of an Internet-based At-home Physical Training Protocol on Quality of Life, Fatigue, Functional Performance, Aerobic Capacity and Muscle Strength in Multiple Sclerosis Patients (clinicaltrials.gov) - May 13, 2016
P=N/A, N=126, Completed, Sponsor: University of Erlangen-Nürnberg
- New trial: Novel Portable Diagnostic Device for Automatic Detection of Relative Afferent Pupillary Defect (clinicaltrials.gov) - May 13, 2016
P=N/A, N=44, Active, not recruiting, Sponsor: Mashhad University of Medical Sciences
- Trial primary completion date: MS-CARE: Multiple Sclerosis-Collaborative Approach to Rehabilitation Effectiveness Study (clinicaltrials.gov) - May 13, 2016
P=N/A, N=200, Enrolling by invitation, Sponsor: University of Washington
Trial primary completion date: Jan 2016 --> Dec 2016 Trial primary completion date: Feb 2016 --> Oct 2016
- Trial primary completion date: Closing the Loop 24/7 in Adolescents With Type 1 Diabetes (clinicaltrials.gov) - May 13, 2016
P=N/A, N=24, Active, not recruiting, Sponsor: University of Cambridge
Trial primary completion date: Feb 2016 --> Oct 2016 Trial primary completion date: Jan 2016 --> Sep 2016
- Trial suspension: Gastrointestinal Transit Time in Patients With Guillain-Barré Syndrome (clinicaltrials.gov) - May 13, 2016
P=N/A, N=30, Suspended, Sponsor: University of Aarhus
Trial primary completion date: Jan 2016 --> Sep 2016 Recruiting --> Suspended
- Trial completion, Retrospective data: H1N1-014VS: A Database Study to Estimate the Risk of Multiple Sclerosis Following Vaccination With Arepanrix™ in Manitoba, Canada (clinicaltrials.gov) - May 13, 2016
P=N/A, N=1, Completed, Sponsor: University of Manitoba
Recruiting --> Suspended Active, not recruiting --> Completed
- Trial completion, HEOR: Effect of Resistance and Aerobic Exercise in CIDP or MMN (clinicaltrials.gov) - May 13, 2016
P=N/A, N=23, Completed, Sponsor: University of Aarhus
Active, not recruiting --> Completed Enrolling by invitation --> Completed
- Trial completion, Trial primary completion date: Cholecalciferol Supplementation on Disease Activity, Fatigue and Bone Mass on Juvenile Systemic Lupus Erythematosus. (clinicaltrials.gov) - May 13, 2016
P=N/A, N=60, Completed, Sponsor: ROSA MARIA RODRIGUES PEREIRA
Enrolling by invitation --> Completed Recruiting --> Completed | Trial primary completion date: Nov 2013 --> Aug 2013
- Trial completion, Enrollment change, Trial primary completion date: Trial of a Physical Activity Intervention for RA Fatigue (clinicaltrials.gov) - May 13, 2016
P=N/A, N=96, Completed, Sponsor: University of California, San Francisco
Recruiting --> Completed | Trial primary completion date: Nov 2013 --> Aug 2013 Active, not recruiting --> Completed | N=120 --> 96 | Trial primary completion date: Jul 2015 --> Mar 2016
- Xeljanz (tofacitinib) / Pfizer
Clinical: Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid Arthritis Patients (clinicaltrials.gov) - May 12, 2016
P4, N=25, Recruiting, Sponsor: University of California, Los Angeles
Active, not recruiting --> Completed | N=120 --> 96 | Trial primary completion date: Jul 2015 --> Mar 2016 Not yet recruiting --> Recruiting
- || Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date, Adherence: Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice (clinicaltrials.gov) - May 12, 2016
P=N/A, N=140, Recruiting, Sponsor: AbbVie
Not yet recruiting --> Recruiting Trial primary completion date: Mar 2017 --> Sep 2017
- Trial primary completion date: A Multi-centre Study to Assess the Long-term Performance of the Summit™ Hip in Primary Total Hip Replacement (clinicaltrials.gov) - May 12, 2016
P4, N=275, Terminated, Sponsor: DePuy International
Trial primary completion date: Mar 2017 --> Sep 2017 Trial primary completion date: Dec 2006 --> Nov 2011
- Orencia (abatacept) / BMS
Preclinical, Enrollment change, Trial withdrawal: Effect on Orencia (Abatacept) on the Apoptosis of T Cells, B Cells and APC Cells in Rheumatoid Arthritis (clinicaltrials.gov) - May 12, 2016
P4, N=0, Withdrawn, Sponsor: University of California, Los Angeles
Trial primary completion date: Dec 2006 --> Nov 2011 N=24 --> 0 | Not yet recruiting --> Withdrawn
- ||| dimethyl fumarate / Generic mfg.
Enrollment closed: Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis. (clinicaltrials.gov) - May 12, 2016
P2, N=71, Active, not recruiting, Sponsor: Biogen
N=24 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting
- Biomarker, Trial completion: Neuroretinal Biomarkers in Neurodegenerative Diseases (clinicaltrials.gov) - May 12, 2016
P=N/A, N=80, Completed, Sponsor: University of Edinburgh
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial completion: Prospective Randomized Endovascular Therapy in Multiple Sclerosis - PREMiSE (clinicaltrials.gov) - May 12, 2016
P2, N=20, Completed, Sponsor: University at Buffalo Neurosurgery
Active, not recruiting --> Completed Recruiting --> Completed
- |||| atorvastatin / Generic mfg.
Trial primary completion date: AdDIT: Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial (clinicaltrials.gov) - May 11, 2016
P3, N=500, Active, not recruiting, Sponsor: University of Cambridge
Recruiting --> Completed Trial primary completion date: Mar 2016 --> Sep 2016
- | Trial completion: Closed Loop Control in Adolescents Using Heart Rate as Exercise Indicator (clinicaltrials.gov) - May 11, 2016
P=N/A, N=18, Completed, Sponsor: Marc Breton
Trial primary completion date: Mar 2016 --> Sep 2016 Recruiting --> Completed
- Enrollment open: Bump2Be: BGAT (Blood Glucose Awareness Training) for Users Who Might Become Pregnant (clinicaltrials.gov) - May 11, 2016
P=N/A, N=58, Recruiting, Sponsor: University of Virginia
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Enrollment closed, Combination therapy: The Safety and Efficacy of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM (clinicaltrials.gov) - May 11, 2016
P3, N=170, Active, not recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- New trial: B1B: Bright 1 Bodies Weight Management Program (clinicaltrials.gov) - May 11, 2016
P=N/A, N=50, Not yet recruiting, Sponsor: Yale University
- Enrollment change: Effects of Sustained Reading on the Ocular Surface (clinicaltrials.gov) - May 10, 2016
P=N/A, N=50, Recruiting, Sponsor: University of Rochester
Recruiting --> Active, not recruiting N=40 --> 50
- New trial: Optic Disc, Macula, and Retinal Nerve Fiber Layer Measurements Obtained by OCT in Thyroid Associated Ophthalmopathy (clinicaltrials.gov) - May 10, 2016
P=N/A, N=102, Completed, Sponsor: Neon Hospital
- Enrollment closed: AERCONN: Exercise in Multiple Sclerosis: Effects on Cognitive Function and Brain Connectivity (clinicaltrials.gov) - May 10, 2016
P=N/A, N=68, Active, not recruiting, Sponsor: Universitätsklinikum Hamburg-Eppendorf
N=40 --> 50 Recruiting --> Active, not recruiting
- Trial completion, Enrollment change, Trial primary completion date: "Medikidz Explain JIA Comic Book- Hebrew" (clinicaltrials.gov) - May 10, 2016
P=N/A, N=4, Completed, Sponsor: Rabin Medical Center
Recruiting --> Active, not recruiting Not yet recruiting --> Completed | N=100 --> 4 | Trial primary completion date: Aug 2016 --> May 2016
- | fingolimod / Generic mfg.
Trial completion: Computerized Exercise Training for Cognitive Remediation in Adults With Multiple Sclerosis Treated With Gilenya (clinicaltrials.gov) - May 10, 2016
P=N/A, N=20, Completed, Sponsor: Stony Brook University
Not yet recruiting --> Completed | N=100 --> 4 | Trial primary completion date: Aug 2016 --> May 2016 Active, not recruiting --> Completed
- Trial primary completion date: Post-transfusion Platelet Count (clinicaltrials.gov) - May 10, 2016
P=N/A, N=65, Recruiting, Sponsor: Region Skane
Active, not recruiting --> Completed Trial primary completion date: Dec 2016 --> Jul 2017
- New trial, MRI: Measuring Cerebral Blood Flow Using Pseudo-continuous Arterial Spin Labeling Perfusion Magnetic Resonance Imaging (clinicaltrials.gov) - May 10, 2016
P=N/A, N=350, Enrolling by invitation, Sponsor: Loma Linda University
- metformin / Generic mfg.
New P4 trial: The Effects of Metformin on Glycemic Control and Insulin Sensitivity in Adolescents With T1DM (clinicaltrials.gov) - May 10, 2016
P4, N=30, Recruiting, Sponsor: Third Affiliated Hospital, Sun Yat-Sen University
- Enrollment change: Marine Oils and Arthritis (clinicaltrials.gov) - May 10, 2016
P=N/A, N=7, Terminated, Sponsor: National Institute of Nutrition and Seafood Research, Norway
Trial primary completion date: Dec 2016 --> Jul 2017 N=80 --> 7
- || methylprednisolone sodium succinate / Generic mfg.
Clinical: A Randomized Study of IVIG vs. IVIG With High Dose Methylprednisolone in Childhood ITP. (clinicaltrials.gov) - May 10, 2016
P3, N=32, Completed, Sponsor: The Hospital for Sick Children
N=80 --> 7 Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Mar 2016
- trichuris suis ova (CNDO-201) / Fortress
Trial termination: TRIOMS: Trichuris Suis Ova (TSO)in Recurrent Remittent Multiple Sclerosis and Clinically Isolated Syndrome (clinicaltrials.gov) - May 6, 2016
P2, N=50, Terminated, Sponsor: Charite University, Berlin, Germany
Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Mar 2016 Recruiting --> Terminated
- | staphylococcal protein A (PRTX-100) / Protalex
Trial completion, P1/2 data, Enrollment change, IO biomarker: SPARTA-II: 6-Month Phase I/II Open Label PRTX-100 in Previous Rheumatoid Arthritis Study Participants and Sera Collection (clinicaltrials.gov) - May 6, 2016
P1/2, N=13, Completed, Sponsor: Protalex, Inc.
Recruiting --> Terminated Recruiting --> Completed | N=20 --> 13
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Observational data, Trial termination: An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNF Therapy (REPEAT) (clinicaltrials.gov) - May 6, 2016
P=N/A, N=1240, Terminated, Sponsor: Hoffmann-La Roche
Recruiting --> Completed | N=20 --> 13 Active, not recruiting --> Terminated
- Lumigan (bimatoprost) / Senju, AbbVie
Trial completion, Trial primary completion date: Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study) (clinicaltrials.gov) - May 6, 2016
P4, N=31, Completed, Sponsor: Cardiff University
Active, not recruiting --> Terminated Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Mar 2016
- Campath (alemtuzumab) / Sanofi, Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial completion, Trial primary completion date: Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia (clinicaltrials.gov) - May 6, 2016
P2, N=136, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Mar 2016 Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> May 2016
- Trial primary completion date: Pancreatic Islet Cell Transplantation - A Novel Approach to Improve Islet Quality and Engraftment (clinicaltrials.gov) - May 6, 2016
P1, N=15, Recruiting, Sponsor: Baylor Research Institute
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> May 2016 Trial primary completion date: Dec 2015 --> Dec 2018
- AMG 357 / Amgen
Trial termination: Study to Evaluate the Safety, Tolerability, and Action of AMG 357 in Females With Rheumatoid Arthritis (clinicaltrials.gov) - May 6, 2016
P1, N=32, Terminated, Sponsor: Amgen
Trial primary completion date: Dec 2015 --> Dec 2018 Recruiting --> Terminated; Study has stopped due to a decision by Amgen to terminate the program
- New P1 trial: Telerehabilitation Upper Extremity for Neurological Disorders (clinicaltrials.gov) - May 6, 2016
P1, N=20, Completed, Sponsor: Fondazione Don Carlo Gnocchi Onlus
- | tabalumab (LY2127399) / Eli Lilly
Trial termination: A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus (clinicaltrials.gov) - May 6, 2016
P3, N=226, Terminated, Sponsor: Eli Lilly and Company
Recruiting --> Terminated; Study has stopped due to a decision by Amgen to terminate the program Completed --> Terminated; Lack of efficacy
- | Humira (adalimumab) / Eisai, AbbVie
Trial completion, Enrollment change: Surveillance of Humira in Korean JIA Patients (clinicaltrials.gov) - May 6, 2016
P=N/A, N=28, Completed, Sponsor: AbbVie
Completed --> Terminated; Lack of efficacy Recruiting --> Completed | N=600 --> 28
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Trial primary completion date: Multicenter, Post-marketing, Non-interventional, Observational Study in RA Patients Treated With RoActemra/Actemra (Tocilizumab) (clinicaltrials.gov) - May 5, 2016
P=N/A, N=400, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Completed | N=600 --> 28 Trial primary completion date: Dec 2016 --> Jun 2017
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Trial initiation date: An Observational Study on Long-Term Efficacy and Safety of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis (FAct) (clinicaltrials.gov) - May 5, 2016
P=N/A, N=215, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Dec 2016 --> Jun 2017 Initiation date: Aug 2009 --> Dec 2010
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment closed: A Non-Interventional Study of RoActemra/Actemra (Tocilizumab) Treatment in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - May 5, 2016
P=N/A, N=169, Active, not recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Aug 2009 --> Dec 2010 Recruiting --> Active, not recruiting
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment closed, Enrollment change: U-Act-After: An Observational Study on Long-Term Efficacy of Tight Control RoActemra/Actemra (Tocilizumab) and/or Methotrexate in Patients With Early Rheumatoid Arthritis Who Have Participated in the U-Act-Early Study (ML22497) (clinicaltrials.gov) - May 5, 2016
P=N/A, N=224, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=300 --> 224
- || Actemra SC (tocilizumab SC) / Roche, Halozyme
Observational data, Trial initiation date, Combination therapy, Monotherapy: EMBRACE-SC: Observational Study of Subcutaneous (SC) Tocilizumab Alone or in Combination With Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) in Rheumatoid Arthritis (clinicaltrials.gov) - May 5, 2016
P=N/A, N=200, Not yet recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | N=300 --> 224 Initiation date: Mar 2016 --> Jul 2016